U.S. patent application number 13/745204 was filed with the patent office on 2013-10-31 for mitochondrial dna deletion between about residues 12317-16254 for use in the detection of cancer.
This patent application is currently assigned to MITOMICS INC.. The applicant listed for this patent is MITOMICS INC.. Invention is credited to Jude Alexander, Jennifer Creed, Gabriel Dakubo, Andrew Harbottle, Andrea Maggrah, Katrina Maki, Ryan Parr, Brian Reguly, Kerry Robinson.
Application Number | 20130288243 13/745204 |
Document ID | / |
Family ID | 40625325 |
Filed Date | 2013-10-31 |
United States Patent
Application |
20130288243 |
Kind Code |
A1 |
Parr; Ryan ; et al. |
October 31, 2013 |
Mitochondrial DNA deletion between about residues 12317-16254 for
use in the detection of cancer
Abstract
The present invention relates to methods for predicting,
diagnosing and monitoring cancer. The methods comprise obtaining
biological samples, extracting mitochondrial DNA (mtDNA) from the
samples, quantifying a mtDNA mutation in the sample and comparing
the level of the mtDNA mutation present in the sample with a
reference value The methods of the invention may also be effective
in screening for new therapeutic agents and treatment regimes
Further, said methods may be also be useful for monitoring the
response of a subject to a preventative or therapeutic
treatment.
Inventors: |
Parr; Ryan; (Thunder Bay,
CA) ; Creed; Jennifer; (Thunder Bay, CA) ;
Robinson; Kerry; (Thunder Bay, CA) ; Maggrah;
Andrea; (Thunder Bay, CA) ; Maki; Katrina;
(Porcupine, CA) ; Dakubo; Gabriel; (Thunder Bay,
CA) ; Reguly; Brian; (Vancouver, CA) ;
Harbottle; Andrew; (Tyne and Wear, GB) ; Alexander;
Jude; (Petawawa, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MITOMICS INC.; |
|
|
US |
|
|
Assignee: |
MITOMICS INC.
Thunder Bay
CA
|
Family ID: |
40625325 |
Appl. No.: |
13/745204 |
Filed: |
January 18, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12742032 |
Aug 25, 2010 |
|
|
|
PCT/CA2008/001956 |
Nov 10, 2008 |
|
|
|
13745204 |
|
|
|
|
61002637 |
Nov 9, 2007 |
|
|
|
Current U.S.
Class: |
435/6.11 |
Current CPC
Class: |
C12Q 2600/156 20130101;
C12Q 2600/158 20130101; C12Q 1/6886 20130101 |
Class at
Publication: |
435/6.11 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68 |
Claims
1. A method of detecting a cancer in a subject, the method
comprising: a) quantifying, in a biological sample obtained from
the subject, the amount of mtDNA having a deletion in the mtDNA
sequence spanning approximately nucleotides 12317 and 16254 of the
human mtDNA genome; b) comparing the amount of mtDNA in the sample
having the deletion to at least one known reference value; and, c)
detecting said cancer based on the results of step (b).
2. The method of claim 1 wherein the deletion has a sequence as set
forth in SEQ ID NO: 1 or SEQ ID NO: 2.
3. The method of claim 1 wherein the at least one known reference
value is the amount of the deletion in a reference sample of mtDNA
from known non-cancerous tissue or body fluid, and wherein an
elevated amount of the deletion in the biological sample compared
to the reference sample is indicative of cancer.
4. (canceled)
5. The method of claim 3 further comprising the step of comparing
the amount of mtDNA in the sample having the deletion to the amount
of the deletion in a reference sample of mtDNA from known cancerous
tissue or body fluid.
6. The method of claim 1 wherein the at least one known reference
value is the amount of the deletion in a reference sample of mtDNA
from known cancerous tissue or body fluid, wherein a similar level
of the deletion in the biological sample compared to the reference
sample is indicative of cancer.
7. (canceled)
8. The method of claim 7 further comprising the step of comparing
the amount of mtDNA in the sample having the deletion to the amount
of the deletion in a reference sample of mtDNA from known
non-cancerous tissue or body fluid.
9. (canceled)
10. The method of claim 1 wherein the step of quantifying includes
first amplifying a target region of mtDNA that is indicative of the
deletion, and quantifying the amount of the amplified target
region.
11. The method of claim 10 wherein a primer having ID NO: 4 is used
as part of a pair of amplification primers for amplifying the
target region.
12. The method of claim 1 wherein the cancer is prostate cancer or
breast cancer.
13-27. (canceled)
28. A method of detecting a cancer in a subject, the method
comprising: a) quantifying, in a biological sample obtained from
the subject, the amount of mtDNA in the sample having a deletion
set forth in SEQ ID NO: 1 or SEQ ID NO: 2; and b) comparing the
amount of mtDNA from step a) to at least one known reference value;
and c) detecting said cancer based on the results of step (b).
29. The method of claim 28 wherein the at least one known reference
value is the amount of SEQ ID NO: 1 or SEQ ID NO: 2 in a reference
sample of mtDNA from known non-cancerous tissue or body fluid.
30. The method of claim 28 wherein the at least one known reference
value is the amount of SEQ ID NO: 1 or SEQ ID NO: 2 in a reference
sample of mtDNA from known cancerous tissue or body fluid.
31. (canceled)
32. The method of claim 31 wherein the step of quantifying includes
first amplifying a target region of mtDNA that is indicative of the
deletion, and quantifying the amount of the amplified target
region.
33. The method of claim 32 wherein one of a pair of primers used in
the amplifying of the target region overlaps a rejoining site of
SEQ ID NO: 1 or SEQ ID NO: 2, after the sequence has
re-circularized.
34. The method of claim 28 wherein the cancer is prostate cancer or
breast cancer.
35-38. (canceled)
39. A diagnostic kit for carrying out the method of claim 1
comprising: (a) at least one of material for collecting one or more
biological samples, material for extracting mtDNA from one or more
biological sample or reagent for conducting the method; and (b) at
least one suitable primer for detecting the mtDNA deletion.
40. The kit of claim 39, wherein the at least one suitable primer
overlaps a spliced region of mtDNA having the deletion.
41. The kit of claim 40, therein the at least one suitable primer
is SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
42. A diagnostic kit for carrying out the method of claim 28
comprising: (a) at least one of material for collecting one or more
biological samples, material for extracting mtDNA from one or more
biological sample or reagent for conducting the method; and (b) at
least one suitable primer for detecting the deletion set forth in
SEQ ID NO: 1 or SEQ ID NO: 2.
43. The kit of claim 43, wherein the at least one suitable primer
overlaps a rejoining site of SEQ ID NO: 1 or SEQ ID NO: 2.
Description
FIELD OF THE INVENTION
[0001] The present invention pertains to the field of mitochondrial
genomics. In particular it is related to the detection of human
mitochondrial genome mutations and their utility as an indicators
of cancer.
BACKGROUND OF THE INVENTION
Mitochondrial DNA as a Diagnostic Tool
[0002] Mitochondrial DNA (mtDNA) sequence dynamics are important
diagnostic tools. Mutations in mtDNA are often preliminary
indicators of developing disease, often associated with nuclear
mutations, and act as biomarkers specifically related to: disease,
such as but not limited to, tissue damage and cancer from smoking
and exposure to second hand tobacco smoke (Lee et al., 1998; Wei,
1998); longevity, based on accumulation of mitochondrial genome
mutations beginning around 20 years of age and increasing
thereafter (von Wurmb, 1998); metastatic disease caused by mutation
or exposure to carcinogens, mutagens, ultraviolet radiation
(Birch-Machin, 2000); osteoarthritis; cardiovascular, Alzheimer,
Parkinson disease (Shoffner et al., 1993; Sherratt et al., 1997;
Zhang et al, 1998); age associated hearing loss (Seidman et al.,
1997); optic nerve degeneration and cardiac dysrhythmia (Brown et
al., 1997; Wallace et al., 1988); chronic progressive external
exophthalmoplegia (Taniike et al., 1992); atherosclerosis (Bogliolo
et al., 1999); papillary thyroid carcinomas and thyroid tumours
(Yeh et al., 2000); as well as others (e.g. Naviaux, 1997; Chinnery
and Turnbull, 1999).
[0003] Mutations at specific sites of the mitochondrial genome can
be associated with certain diseases. For example, mutations at
positions 4216, 4217 and 4917 are associated with Leber's
Hereditary Optic Neuropathy (LHON) (Mitochondrial Research Society;
Huoponen (2001); MitoMap). A mutation at 15452 was found in 5/5
patients to be associated with ubiquinol cytochrome c reductase
(complex III) deficiency (Valnot et al. 1999).
[0004] Specifically, these mutations or alterations include point
mutations (transitions, transversions), deletions (one base to
thousands of bases), inversions, duplications, (one base to
thousands of bases), recombinations and insertions (one base to
thousands of bases). In addition, specific base pair alterations,
deletions, or combinations thereof have been found to be associated
with early onset of prostate, skin, and lung cancer, as well as
aging (e.g. Polyak et al., 1998), premature aging, exposure to
carcinogens (Lee et al., 1998), etc.
Prostate Cancer
[0005] Prostate cancer is a frequently diagnosed solid tumour that
most likely originates in the prostate epithelium (Huang et al.
1999). In 1997, nearly 10 million American men were screened for
prostate specific antigen (PSA), the presence of which suggests
prostate cancer (Woodwell, 1999). Indeed, this indicates an even
higher number of men screened by an initial digital rectal exam
(DRE). In the same year, 31 million men had a DRE (Woodwell, 1999).
Moreover, the annual number of newly diagnosed cases of prostate
cancer in the United States is estimated at 179,000 (Landis et al.,
1999). It is the second most commonly diagnosed cancer and second
leading cause of cancer mortality in Canadian men. In 1997 prostate
cancer accounted for 19,800 of newly diagnosed cancers in Canadian
men (28%) (National Cancer Institute of Canada). It is estimated
that 30% to 40% of all men over the age of forty-nine (49) have
some cancerous prostate cells, yet only 20% to 25% of these men
have a clinically significant form of prostate cancer
(SpringNet--CE Connection, internet,
www.springnet.com/ce/j803a.htm). Prostate cancer exhibits a wide
variety of histological behaviour involving both endogenous and
exogenous factors, i.e. socio-economic situations, diet, geography,
hormonal imbalance, family history and genetic constitution
(Konishi et al. 1997; Hayward et al. 1998). Although certain mtDNA
alterations have been previously associated with prostate cancer,
the need exists for further markers for the detection of prostate
cancer.
Breast Cancer
[0006] Breast cancer is a cancer of the glandular breast tissue and
is the fifth most common cause of cancer death. In 2005, breast
cancer caused 502,000 deaths (7% of cancer deaths; almost 1% of all
deaths) worldwide (World Health Organization Cancer Fact Sheet No.
297). Among women worldwide, breast cancer is the most common
cancer and the most common cause of cancer death (World Health
Organization Cancer Fact Sheet No. 297). Although certain mtDNA
alterations have been previously associated with breast cancer, for
example in Parrella et al. (Cancer Research: 61, 2001), the need
exists for further markers for the detection of breast cancer.
[0007] This background information is provided for the purpose of
making known information believed by the applicant to be of
possible relevance to the present invention. No admission is
necessarily intended, nor should be construed, that any of the
preceding information constitutes prior art against the present
invention.
SUMMARY OF THE INVENTION
[0008] The present invention pertains to mitochondrial DNA
mutations for use in the detection of cancer. In accordance with an
aspect of the present invention, there is provided a method of
detecting a cancer in an individual comprising: [0009] a) obtaining
a biological sample from the individual; [0010] b) extracting
mitochondrial DNA (mtDNA) from the sample; [0011] c) quantifying
the amount of mtDNA in the sample having a deletion in the mtDNA
sequence between about residue 12317 and about residue 16254 of the
human mtDNA genome; and [0012] d) comparing the amount of mtDNA in
the sample having the deletion to at least one known reference
value.
[0013] In accordance with another aspect of the present invention,
there is provided a method of monitoring an individual for the
development of a cancer comprising: [0014] a) obtaining a
biological sample; [0015] b) extracting mitochondrial DNA (mtDNA)
from the sample; [0016] c) quantifying the amount of mtDNA in the
sample having a deletion in the mtDNA sequence between about
residue 12317 and about residue 16254 of the human mtDNA genome;
and [0017] d) repeating steps a) to c) over a duration of time;
[0018] wherein an increasing level of the deletion over the
duration of time is indicative of cancer.
[0019] In accordance with another aspect of the present invention,
there is provided a method of detecting a cancer in an individual
comprising: [0020] a) obtaining a biological sample from the
individual; [0021] b) extracting mitochondrial DNA (mtDNA) from the
sample; [0022] c) quantifying the amount of mtDNA in the sample
having a sequence corresponding to the sequence as set forth in SEQ
ID NO: 1 or SEQ ID NO: 2; and [0023] d) comparing the amount of
mtDNA in the sample corresponding to SEQ ID NO: 1 or SEQ ID NO: 2
to at least one known reference value.
[0024] In accordance with another aspect of the present invention,
there is provided a diagnostic kit for carrying out the method of
the invention comprising:
[0025] (a) material for collecting one or more biological samples;
and
[0026] (b) suitable primers and reagents for detecting the mtDNA
deletion.
BRIEF DESCRIPTION OF THE FIGURES
[0027] These and other features of the invention will become more
apparent in the following detailed description in which reference
is made to the appended drawings.
[0028] FIG. 1 is a graph showing cycle threshold as related to
Example 1.
[0029] FIG. 2 shows a ROC curve illustrating the specificity and
sensitivity of one embodiment of the present invention.
[0030] FIG. 3 is a graph showing cycle threshold as related to
Example 2.
[0031] FIG. 4 shows a ROC curve illustrating the specificity and
sensitivity of another embodiment of the present invention.
[0032] FIG. 5 is a schematic diagram showing the design and
sequence of a primer useful for the detection of the 4 kb
deletion.
[0033] FIG. 6 shows a ROC curve illustrating the specificity and
sensitivity of another embodiment of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0034] The present invention provides methods of predicting,
diagnosing and monitoring cancer. The methods comprise obtaining
one or more biological samples, extracting mitochondrial DNA
(mtDNA) from the samples, quantifying the amount of a mitochondrial
mutation in the samples and comparing the quantity of the mutation
in a sample with a reference value. In this regard, the methods
provide a comprehensive tool for determining disease onset and for
assessing the predisposition of an individual to cancer. The
methods also allow for the monitoring of an individual's risk
factors over time and/or for monitoring a patient's response to
therapeutic agents and treatment regimes.
Definitions
[0035] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs.
[0036] As used herein, the term "about" refers to an understood
variation from the stated value. It is to be understood that such a
variation is always included in any given value provided herein,
whether or not it is specifically referred to.
[0037] As defined herein, "biological sample" refers to a tissue or
bodily fluid containing cells from which mtDNA can be obtained. For
example, the biological sample can be derived from tissue such as
breast or prostate tissue, or from blood, saliva, cerebral spinal
fluid, sputa, urine, mucous, synovial fluid, peritoneal fluid,
amniotic fluid and the like. The biological sample may be a
surgical specimen or a biopsy specimen. The biological sample can
be used either directly as obtained from the source or following a
pre-treatment to modify the character of the sample. Thus, the
biological sample can be pre-treated prior to use by, for example,
preparing plasma or serum from blood, disrupting cells, preparing
liquids from solid materials, diluting viscous fluids, filtering
liquids, distilling liquids, concentrating liquids, inactivating
interfering components, adding reagents, and the like.
[0038] As used herein, "cycle threshold" (C.sub.T) is the point at
which target amplification using real-time PCR rises above
background, as indicated by a signal such as a fluorescence signal.
The C.sub.T is inversely related to the quantity of the sequence
being investigated.
[0039] As used herein, "diagnostic" or "diagnosing" means using the
presence or absence of a mutation or combination of mutations as a
factor in disease diagnosis or management. The detection of the
mutation(s) can be a step in the diagnosis of a disease.
[0040] As used herein, "deletion" means removal of a region of
mtDNA from a contiguous sequence of mtDNA. Deletions can range in
size from one base to thousands of bases or larger.
[0041] As used herein, "mitochondrial DNA" or "mtDNA" is DNA
present in mitochondria.
[0042] As used herein, "mutation" encompasses any modification or
change in mitochondrial DNA from the wild type sequence, including
without limitation point mutations, transitions, insertions,
transversions, translocations, deletions, inversions, duplications,
recombinations or combinations thereof. The modification or change
of the sequence can extend from a single base change to the
addition or elimination of an entire DNA fragment.
[0043] As defined herein, "sensitivity" refers to the fraction of
true positives (true positive rate) results obtained using the
method of the present invention.
[0044] As defined herein, "specificity" refers to the fraction of
false positives (false positive rate) results obtained using the
method of the present invention.
[0045] The terms "therapy" and "treatment," as used interchangeably
herein, refer to an intervention performed with the intention of
improving a subject's status. The improvement can be subjective or
objective and is related to ameliorating the symptoms associated
with, preventing the development of, or altering the pathology of a
disease. Thus, the terms therapy and treatment are used in the
broadest sense, and include the prevention (prophylaxis),
moderation, reduction, and curing of a disease, at various stages.
Preventing deterioration of a subject's status is also encompassed
by the term. Subjects in need of therapy/treatment thus include
those already having the disease, as well as those prone to, or at
risk of developing, the disease, and those in whom the disease is
to be prevented.
Assays for Predicting, Diagnosing and Monitoring Cancer
Assay for Detection of Mitochondrial Mutation
[0046] Mitochondrial DNA (mtDNA) dynamics are an important
diagnostic tool. Mutations in mtDNA are often preliminary
indicators of developing disease and may act as biomarkers
indicative of risk factors associated with disease onset. As
discussed herein, measuring the level of mitochondrial DNA
aberration in a biological sample can determine the presence of one
or more cancers and identify the potential risk or predisposition
of a patient to one or more cancers. Furthermore, measurement of
mtDNA at regular intervals can provide health care professionals
with a real-time, quantitative monitoring tool for measuring the
progression of a patient over time and/or as an assessment for
treatment recommendations in order to determine their effectiveness
in preventing or treating cancer.
[0047] The present invention, therefore, provides methods for
predicting, diagnosing or monitoring cancer, comprising obtaining
one or more biological samples, extracting mitochondrial DNA
(mtDNA) from the samples, and assaying the samples for
mitochondrial mutation by: quantifying the amount of an mtDNA
aberration in the sample and comparing the level of the aberration
with a reference value. As would be understood by those of skill in
the art, the reference value is based on whether the method seeks
to predict, diagnose or monitor cancer. Accordingly, the reference
value may relate to mtDNA data collected from one or more known
non-cancerous biological samples, from one or more known cancerous
biological samples, and/or from one or more biological samples
taken over time. These reference values are used for comparison
with the mtDNA data collected from the one or more biological
samples wherein, for example, a similar or elevated amount of
deletion in the biological sample compared to the reference sample
is indicative of a predisposition to or the onset of cancer, or
wherein an increasing level of the deletion over time is indicative
of cancer onset.
[0048] In accordance with an aspect of the invention, the methods
for predicting, monitoring and diagnosing cancer comprise an assay
for detecting and quantifying one or more mitochondrial mutations.
In accordance with one embodiment of the invention, the mutation is
an mtDNA deletion. In accordance with another embodiment, the
mutation is an mtDNA deletion of 3926 bp of mtDNA (referred to
herein as "the 4 kb deletion" or "4 kb sequence"). In accordance
with yet another embodiment, the mutation is an mtDNA deletion
having the sequence as set forth in SEQ ID NO:1 or SEQ ID NO:2,
there being no difference between SEQ ID NO: 1 and SEQ ID NO: 2
when in circular form.
[0049] The 4 kb deletion spans approximately nucleotides 12317 and
16254 of the human mtDNA genome. The human mtDNA genome is listed
herein as SEQ ID NO:3 (Genbank accession no. AC.sub.--000021). The
4 kb deletion is characterized by direct flanking repeats 12 bp in
size, with the repeats located at positions 12317-12328 and 16243
to 16254. The repeat sequence is 5'-TGCAACTCCAAA-3'. Thus, in
accordance with one embodiment of the invention, the mutation is an
mtDNA deletion of between about residue 12317 and about residue
16254 of the human mtDNA genome.
[0050] The inventors have determined, as provided by way of example
below, that this deletion is associated with cancer and in
particular prostate and breast cancer. Therefore, such deletion
provides an accurate biomarker and, therefore, a valuable tool for
the detection, diagnosis, or monitoring of cancer in at least these
tissues.
[0051] The deletion results in the creation of two deletion
monomers, one of 4 kb in size (small sublimon) and one of
approximately 12.5 kb in size (large sublimon). The occurrence of
the deletion may be detected by either identifying the presence of
the small sublimon or the large sublimon, the 4 kb or 12.5 kb
sequence respectively.
[0052] Exemplary methods for assaying the mitochondrial mutation
are provided in the Example section. Extraction of mtDNA from a
sample may be undertaken using any suitable known method. MtDNA
extraction is followed by amplification of all or a region of the
mitochondrial genome, and may include sequencing of the
mitochondrial genome, as is known in the art and described, for
example, in Current Protocols in Molecular Biology (Ausubel et al.,
John Wiley & Sons, New York, 2007). Likewise, methods for
detecting the presence of mutations in the mtDNA can be selected
from suitable techniques known to those skilled in the art. For
example, analyzing mtDNA can comprise sequencing the mtDNA,
amplifying mtDNA by PCR, Southern, Northern, Western South-Western
blot hybridizations, denaturing HPLC, hybridization to microarrays,
biochips or gene chips, molecular marker analysis, biosensors,
melting temperature profiling or a combination of any of the
above.
[0053] Any suitable means to sequence mitochondrial DNA may be
used. Preferably, mtDNA is amplified by PCR prior to sequencing.
The method of PCR is well known in the art and may be performed as
described in Mullis and Faloona, 1987, Methods Enzymol., 155: 335.
PCR products can be sequenced directly or cloned into a vector
which is then placed into a bacterial host. Examples of DNA
sequencing methods are found in Brumley, R. L. Jr. and Smith, L.
M., 1991, Rapid DNA sequencing by horizontal ultrathin gel
electrophoresis, Nucleic Acids Res. 19:4121-4126 and Luckey, J. A.,
et al, 1993, High speed DNA sequencing by capillary gel
electrophoresis, Methods Enzymol. 218: 154-172. The combined use of
PCR and sequencing of mtDNA is described in Hopgood, R., et al,
1992, Strategies for automated sequencing of human mtDNA directly
from PCR products, Biotechniques 13:82-92 and Tanaka, M. et al,
1996, Automated sequencing of mtDNA, Methods Enzymol. 264:
407-421.
[0054] Although real-time quantitative PCR methods, as described in
the examples below, represent the preferred means for detecting and
quantifying the presence or absence of the 4 kb deletion, other
methods would be well known to an individual of skill in the art
and could be utilized as indicated above. In addition,
quantification of the deletion could be made using Bio-Rad's
Bioplex.TM. System and Suspension Array technology. Generally, the
method requires amplification and quantification of sequences using
any known methods.
[0055] The following primer sequences are examples of primers that
may be used for the detection of the 4 kb deletion:
TABLE-US-00001 4 forward (binds to bases 12313-12328/16255-16267 of
the human mtDNA genome) (SEQ ID NO: 4)
5'-TTGGTGCAACTCCAAAGCCACCCCTCACC-3'; 4 reverse (binds to bases
16391-16409 of the human mtDNA genome) (SEQ ID NO: 5)
5'-AGGATGGTGGTCAAGGGAC-3'.
[0056] In one embodiment of the present invention, a pair of
amplification primers are used to amplify a target region
indicative of the presence of the 4 kb deletion. In this
embodiment, one of the pair of amplification primers overlaps a
spliced region of mtDNA after deletion of the 4 kb sequence has
occurred and the mtDNA has reformed as a circular mtDNA molecule
(eg. a splice at a position between 12328 and 16255 of the mtDNA
genome). Therefore, extension of the overlapping primer can only
occur if the 4 kb section is deleted. FIG. 5 is a schematic diagram
showing the design and sequence of the primer (ie. SEQ ID NO:
4).
[0057] In another embodiment of the present invention, a pair of
amplification primers are used to amplify a target region
associated with the deleted 4 kb sequence. The deleted 4 kb
sequence, upon deletion, may reform as a circular mtDNA molecule.
In this embodiment, one of the pair of amplification primers
overlaps the rejoining site of the ends of the 4 kb sequence. Thus,
an increase in the amount of the 4 kb molecule detected in a sample
is indicative of cancer.
[0058] In still another embodiment of the present invention, the
breakpoint of the deletion is unknown thereby resulting in two
possibilities for primer location. In this embodiment, two separate
forward primers may be designed to amplify the target region
associated with the deleted 4 kb sequence. The following primer
sequences are examples of those that may be used for the detection
of the 4 kb deletion in this scenario:
TABLE-US-00002 Forward Primers: Primer A (binds to bases
12313-12328/16255-16267 of the human mtDNA genome) (SEQ ID NO: 4)
5'-TTGGTGCAACTCCAAAGCCACCCCTCACC-3'; Primer B (binds to bases
12302-12316 of the human mtDNA genome) (SEQ ID NO: 6)
5'-CCCAAAAATTTTGGTGCAACTCCAAAGCCAC-3'. Reverse Primer: Primer C
(binds to bases 16391-16409 of the human mtDNA genome) (SEQ ID NO:
5) 5'-AGGATGGTGGTCAAGGGAC-3'.
[0059] As would be understood by a person of skill in the art, the
forward primers A or B can be used with reverse primer C to create
PCR products that are useful in qPCR assays.
Biological Sample
[0060] The present invention provides for diagnostic tests which
involve obtaining or collecting one or more biological samples. In
the context of the present invention, "biological sample" refers to
a tissue or bodily fluid containing cells from which mtDNA can be
obtained. For example, the biological sample can be derived from
tissue including, but not limited to, breast, prostate, nervous,
muscle, heart, stomach, colon tissue and the like; or from blood,
saliva, cerebral spinal fluid, sputa, urine, mucous, synovial
fluid, peritoneal fluid, amniotic fluid and the like. The
biological sample may be obtained from a cancerous or non-cancerous
tissue and may be a surgical specimen or a biopsy specimen.
[0061] The biological sample can be used either directly as
obtained from the source or following a pre-treatment to modify the
character of the sample. Thus, the biological sample can be
pre-treated prior to use by, for example, preparing plasma or serum
from blood, disrupting cells, preparing liquids from solid
materials, diluting viscous fluids, filtering liquids, distilling
liquids, concentrating liquids, inactivating interfering
components, adding reagents, and the like.
[0062] One skilled in the art will understand that more than one
sample type may be assayed at a single time (i.e. for the detection
of more than one cancer). Furthermore, where a course of
collections are required, for example, for the monitoring of risk
factors or cancer over time, a given sample may be diagnosed alone
or together with other sample taken throughout the test period. In
this regard, biological samples may be taken once only, or at
regular intervals such as biweekly, monthly, semi-annually or
annually.
[0063] One of skill will also appreciate that mitochondrial DNA
targets are in much greater abundance (approximately 1000 fold
greater) than nucleic acid targets and as such sample sizes
comprising extremely low yields of nucleic acids would be suitable
for use with the present invention.
Applications for Predicating, Diagnosing and Monitoring Cancer
Diagnosing and Monitoring Cancer
[0064] The prevalence of cancer in most tissue types and age groups
necessitates the availability of a tool to not only detect the
presence of cancer, but also to monitor the success and
appropriateness of preventative measures and therapies being
advised to prevent onset, progression and spread of the disease.
Measuring the level of mitochondrial DNA deletions in one or more
biological samples of an individual can provide initial diagnosis
of risk factors, cancer and/or stages of the disease.
[0065] The system and method of the present invention, for example,
may be used to detect cancer at an early stage, and before any
histological abnormalities. Furthermore, sample testing at regular
intervals such as biweekly, monthly, semi-annually or annually (or
any other suitable interval) can provide health care professionals
with a real-time, quantitative monitoring tool to compare against
treatment recommendations to determine their effectiveness in
preventing or treating the disease.
[0066] Turning now to the examples, in one embodiment the present
invention may be used for detecting the presence of pre-neoplasia,
neoplasia and progression towards potential malignancy of prostate
cancer and breast cancer. In one aspect, the present invention
involves the detection and quantification of the 4 kb mtDNA
deletion for the detection, diagnosis, and/or monitoring of cancer.
In this method, mtDNA is extracted from a biological sample (for
example body tissue, or body fluids such as urine, prostate massage
fluid). The extracted mtDNA is then tested in order to determine
the levels (ie. quantity) of the 4 kb deletion in the sample. In
tests conducted by the present inventors, the levels of the
deletion were found to be elevated in samples obtained from
subjects with cancer when compared to samples obtained from
subjects without cancer. Based on the information and data supplied
below, the inventors have concluded that elevated levels of the 4
kb deletion in human mtDNA is indicative of cancer.
[0067] In another embodiment, samples of, for instance prostate
tissue, prostate massage fluid, urine or breast tissue, are
obtained from an individual and tested over a period of time (eg.
years) in order to monitor the genesis or progression of cancer.
Increasing levels of the 4 kb deletion over time could be
indicative of the beginning or progression of cancer.
[0068] One of ordinary skill in the art will appreciate that
analysing one or more biological samples from an individual for
quantification of a mitochondrial DNA target provides a means for a
health care worker to monitor the effectiveness of treatment
regimes. One of ordinary skill will also appreciate the utility of
mtDNA analysis for use by health care providers in identifying (and
providing recommendations for) lifestyle habits, such as poor diet
and exercise, or activities that cause over exposure of an
individual to known carcinogens (eg. tobacco, pollutants).
[0069] Another aspect of the invention provides methods for
confirming or refuting the results of a cancer biopsy test from a
biopsy sample (eg. prostate or breast cancer), comprising:
obtaining non-cancerous tissue from a biopsy sample; and detecting
and quantifying the amount of the 4 kb mtDNA deletion in the
non-diseased tissue.
Determining Genetic Predisposition to Cancer
[0070] In order to fully evaluate an individual's risk of one or
more cancers it is imperative that health care providers are
provided with as much information as possible to understand and
communicate their patient's risk factors. The utilization of the
present invention to determine the level of mtDNA aberration will
not only prove helpful in assessing an individual's susceptibility
to one or more cancers, it provides a valuable tool to identify
patients with greater risk who are potentially in need of more
aggressive monitoring and treatment measures.
[0071] In this regard, the various examples provided below
illustrate a difference in the amount of mtDNA having the 4 kb
deletion between samples obtained from subjects having cancer, and
subjects without cancer. The amount of the 4 kb deletion was found
to be higher in the samples obtained from subjects having cancer.
This determination was made by comparing the amount of the 4 kb
deletion in the samples from known cancer cells and/or known
non-cancer cells.
[0072] As such, the inventors determined that screening of
biological samples would prove useful in identifying an
individual's predisposition to one or more cancers. Thus, in
accordance with one embodiment of the present invention there is
provided a method for screening individuals for cancer from one or
more biological samples comprising: obtaining the one or more
samples, and detecting and quantifying the level of the 4 kb mtDNA
deletion in the samples. In a specific embodiment of the invention,
there is provided a method for screening individuals for prostate
or breast cancer from a body fluid or tissue sample comprising;
obtaining the body fluid or tissue sample, and detecting and
quantifying the level of the 4 kb mtDNA deletion in the body fluid
or tissue sample.
[0073] Age related accumulation of the 4 kb mtDNA deletion may also
predispose an individual to, for example, prostate cancer or breast
cancer, which is prevalent in middle aged and older men, and middle
aged and older women, respectively. Similarly, an accumulation of
the 4 kb mtDNA deletion may be associated with a particular
lifestyle based on an individual's diet, exercise habits, and
exposure to known carcinogens. Thus, in accordance with one aspect
of the invention, a method is provided wherein regular cancer
screening may take place by monitoring over time the amount of the
4 kb deletion in one or more biological samples, non-limiting
examples of which include breast and prostate tissues or body
fluids such as prostate massage fluid, or urine.
Evaluation of Therapeutic Agents
[0074] The method of the present invention may also be used for
screening potential therapeutic agents for use in cancer treatment
or for monitoring the therapeutic effect of such agents. The method
of the present invention may be used to measure various biomarkers
associated with the cancers identified herein. The ability to
assess the level of DNA damage in any biological sample at any time
point provides the foundation for a unique and informative
screening test for an individual's health and to assess the safety
and efficacy of existing and new therapeutic agents and treatment
regimes. Furthermore, by identifying the specific genetic changes
underlying a subject's state of health, it may be readily
determined whether and to what extent a patient will respond to a
particular therapeutic agent or regime.
Kits
[0075] The present invention provides diagnostic/screening kits for
use in a clinical environment. Such kits could not only include one
or more sampling means, but other materials necessary for the
identification of mtDNA mutations.
[0076] The kits can optionally include reagents required to conduct
a diagnostic assay, such as buffers, salts, detection reagents, and
the like. Other components, such as buffers and solutions for the
isolation and/or treatment of a biological sample, may also be
included in the kit. One or more of the components of the kit may
be lyophilised and the kit may further comprise reagents suitable
for the reconstitution of the lyophilised components.
[0077] Where appropriate, the kit may also contain reaction
vessels, mixing vessels and other components that facilitate the
preparation of the test sample. The kit may also optionally include
instructions for use, which may be provided in paper form or in
computer-readable form, such as a disc, CD, DVD or the like.
[0078] In one aspect of the invention there is provided a kit for
diagnosing cancer comprising means for extraction of mtDNA,
primers, reagents and instructions.
[0079] In another aspect of the invention there is provided a kit
for diagnosing cancer, for example prostate or breast cancer,
comprising means for extraction of mtDNA, primers having the
nucleic acid sequences recited in SEQ ID NOs: 4 and 5, reagents and
instructions.
[0080] In another aspect of the invention there is provided a kit
for diagnosing cancer, for example prostate or breast cancer,
comprising means for extraction of mtDNA, primers having the
nucleic acid sequences recited in SEQ ID NOs: 6 and 5, reagents and
instructions.
[0081] To gain a better understanding of the invention described
herein, the following examples are set forth. It will be understood
that these examples are intended to describe illustrative
embodiments of the invention and are not intended to limit the
scope of the invention in any way.
EXAMPLES
Example 1
Association of Prostate Cancer with 4 kb Deletion in Human
mtDNA
[0082] Urine samples were collected from five patients who had been
diagnosed with prostate cancer and five who had a needle biopsy
procedure which was unable to detect prostate malignancy. These
samples were collected following a digital rectal exam (DRE) to
facilitate the collection of prostate cells.
[0083] Upon receipt of the samples a 5 ml aliquot was removed and
then 2 mls were centrifuged at 14,000.times.g to form a pellet. The
supernatant was removed and discarded.
[0084] Pellets were resuspended in 200 ul phosphate buffered saline
solution. Both the resuspended pellet and the whole urine sample
were subjected to a DNA extraction procedure using the QiaAMP DNA
Mini Kit (Qiagen P/N 51304) according to the manufacturer's
directions. The resulting DNA extracts were then quantified using a
NanoDrop ND-1000 Spectrophotometer and normalized to a
concentration of 0.1 ng/ul.
[0085] Samples were analyzed by quantitative real-time PCR with the
4 kb deletion specific primers according to the following:
[0086] 1.times. iQ SYBR Green Supermix (Bio-Rad product no.
170-8880)
[0087] 100 nmol forward primer
(5'-TTGGTGCAACTCCAAAGCCACCCCTCACC-3') (SEQ ID NO: 4)
[0088] 100 nmol reverse primer (5'-AGGATGGTGGTCAAGGGAC-3') (SEQ ID
NO: 5)
[0089] 1 ng template DNA in a 25 ul reaction
[0090] Reactions were cycled on an Opticon 2 DNA Engine (Bio-Rad
Canada) according to the following protocol: [0091] 1. 95.degree.
C. for 3 minutes [0092] 2. 95.degree. C. for 30 seconds [0093] 3.
69.degree. C. for 30 seconds [0094] 4. 72.degree. C. for 30 seconds
[0095] 5. Plate Read [0096] 6. Repeat steps 2-5 44 times [0097] 7.
72.degree. C. for 10 minutes [0098] 8. Melting Curve from
50.degree. C. to 105.degree. C., read every 1.degree. C., hold for
3 seconds [0099] 9. 10.degree. C. Hold
Results
[0100] Results from the urine pellet did not yield significant
differences in the mean cycle threshold observed or a useful cutoff
point. However, the results from the whole urine sample did yield
significant differences as provided below.
[0101] Tables 1 and 2, and FIG. 1 show the difference in the mean
C.sub.T scores for urine samples from subjects having prostate
malignant tissue and benign tissue at the 0.04 significance
level.
TABLE-US-00003 TABLE 1 Mean Values for C.sub.T scores: Urine
Samples Std. Error N Mean Std. Deviation Mean Benign 7 38.0357
3.40974 1.288876 Malignant 7 31.9300 6.12583 2.31534
TABLE-US-00004 TABLE 2 Significance Test for Mean C.sub.T scores
Independent Samples Test Levene's Test for Test for Equality Means
Equality 95% Confidence of Sig. Std. Interval of the CTt40
Variances (2- Mean Error Difference fluid F Sig. t df tailed) Diff.
Diff. Lower Upper Equal 1.707 .216 2304 12 .040 610571 264985
.33218 11.87925 variances assumed Equal 2304 9392 .046 610571
264985 .14927 12.06215 variances not assumed
[0102] Tables 3 and 4, and FIG. 2 illustrate that when using a
cut-off cycle threshold of 36.255 the sensitivity of the assay for
prostate cancer is 86% and the specificity is 86%.
[0103] FIG. 2 is a Receiver Operating Characteristic (ROC) curve
illustrating the specificity and sensitivity of the 4 kb mtDNA
deletion as a marker for prostate cancer when testing urine. These
results were obtained using a cutoff C.sub.T of 36.255. The
sensitivity of the marker at this C.sub.T is 86%, while the
specificity is 86%.
[0104] The determination of the cutoff C.sub.T of 36.255 is shown
in Table 3. The results listed in Table 3 show that a cutoff
C.sub.T of 36.255 provided the highest sensitivity and
specificity.
[0105] The accuracy of the test depends on how well the test
separates the group being tested into those with and without the
prostate cancer. Accuracy is measured by the area under the ROC
curve. Table 4 shows the calculation of the area under the curve
for the present example.
TABLE-US-00005 TABLE 3 Determination of Specificity and Sensitivity
Positive if .ltoreq..sup.a Sensitivity 1 - specificity 19.86 .000
.000 24.87 .143 .000 29.48 .286 .000 30.54 .429 .000 32.235 .429
.143 33.77 .571 .143 35.11 .714 .143 36.255 .857 .143 37.415 .857
.286 39.23 .857 .429 39.995 1.000 .429 40.21 1.000 .857 41.42 1.000
1.000 .sup.athe smallest cutoff value is the minimum observed test
value minus 1 and the largest cutoff value is the maximum observed
test value plus 1. All the other cutoff values are the averages of
two consecutive ordered observed test values.
TABLE-US-00006 TABLE 4 Results Showing Area Under the ROC Curve
Asymptotic 95% Confidence Interval Area Std. Error.sup.a Asymptotic
Sig..sup.b Lower bound Upper bound .878 .096 .018 .689 1.066 Notes:
.sup.aunder the non-parametric assumption .sup.bnull hypothesis:
true area = 0.5
Example 2
Association of Breast Cancer with 4 kb Deletion in Human mtDNA
[0106] Twenty breast tissue samples were collected, ten of which
were malignant and ten of which had benign breast disease or no
abnormalities. These samples were formalin-fixed paraffin embedded
and 20 micron sections of each were cut into individual sample
tubes for extraction according to the manufacturer's protocol for
the QiaAMP DNA Mini Kit (Qiagen P/N 51304). DNA was then quantified
using a Nanodrop ND-1000 and normalized to a concentration of 2
ng/ul.
[0107] Samples were then assayed for the levels of the 4 kb
deletion by quantitative real-time PCR using the following
protocol:
TABLE-US-00007 X iQ SYBR Green Supermix (Bio-Rad product no.
170-8880) 175 nmol forward primer (SEQ ID NO: 4)
(5'-TTGGTGCAACTCCAAAGCCACCCCTCACC-3') 175 nmol reverse primer (SEQ
ID NO: 5) (5'-AGGATGGTGGTCAAGGGAC-3')
[0108] 20 ng template DNA in a 25 ul reaction
[0109] Reactions were cycled on an Opticon 2 DNA Engine (Bio-Rad
Canada) according to the following protocol: [0110] 1. 95.degree.
C. for 3 minutes [0111] 2. 95.degree. C. for 30 seconds [0112] 3.
70.degree. C. for 30 seconds [0113] 4. 72.degree. C. for 30 seconds
[0114] 5. Plate Read [0115] 6. Repeat steps 2-5 44 times [0116] 7.
72.degree. C. for 10 minutes [0117] 8. Melting Curve from
50.degree. C. to 105.degree. C., read every 1.degree. C., hold for
3 seconds [0118] 9. 10.degree. C. Hold
[0119] Tables 5 and 6, and FIG. 3 show the difference in the mean
C.sub.T scores for breast tissue samples from subjects having
malignant breast tissue and benign breast tissue at the 0.065
level.
TABLE-US-00008 TABLE 5 Mean Values for C.sub.T scores: Breast
Tissue Samples Group N Mean Std. Dev. Std. Error Mean Normal 9
21.5278 2.71939 .90646 Malignant 9 18.9089 2.89126 .96375
TABLE-US-00009 TABLE 6 Significance Test for Mean C.sub.T scores
Levene's Test for Equality Means Test for 95% Equality Confidence
of Sig. Std. Interval of the Variances (2- Mean Error Difference
CTt40 fluid F Sig. t df tailed) Diff. Diff. Lower Upper Equal .007
.934 1.979 16 .065 2.61889 1.32306 -.18588 5.42366 variances
assumed Equal 1.979 15.94 .065 2.61889 1.32306 -.18674 5.42452
variances not assumed
[0120] Tables 7 and 8, and FIG. 4 illustrate that when using a
cut-off cycle threshold of 19.845 the sensitivity of the assay for
breast cancer is 78% and the specificity is 78%.
[0121] FIG. 4 is an ROC curve illustrating the specificity and
sensitivity of the 4 kb mtDNA deletion as a marker for breast
cancer when testing breast tissue. These results were obtained
using a cutoff C.sub.T of 19.845. The sensitivity of the marker at
this C.sub.T is 78%, while the specificity is 78%.
[0122] The determination of the cutoff C.sub.T of 19.845 is shown
in Table 7. The results listed in Table 7 show that a cutoff
C.sub.T of 19.845 provided the highest sensitivity and
specificity.
[0123] The accuracy of the test depends on how well the test
separates the group being tested into those with and without the
breast cancer. Accuracy is measured by the area under the ROC
curve. Table 8 shows the calculation of the area under the curve
for the present example.
TABLE-US-00010 TABLE 7 Determination of Specificity and Sensitivity
Positive if .ltoreq..sup.a Sensitivity 1 - specificity 15.28 .000
.000 16.305 .111 .000 16.69 .222 .000 17.075 .333 .000 17.4 .444
.000 17.71 .556 .000 18.0 .556 .111 18.835 .556 .222 19.415 .667
.222 19.845 .778 .222 20.475 .778 .333 10.79 .778 .444 21.38 .778
.556 22.005 .778 .667 23.145 .889 .667 24.19 .889 .778 24.49 .889
.889 25.21 1.00 .889 26.66 1.00 1.00 .sup.athe smallest cutoff
value is the minimum observed test value minus 1 and the largest
cutoff value is the maximum observed test value plus 1. All the
other cutoff values are the averages of two consecutive ordered
observed test values.
TABLE-US-00011 TABLE 8 Results Showing Area Under the ROC Curve
Asymptotic 95% Confidence Interval Area Std. Error.sup.a Asymptotic
Sig..sup.b Lower bound Upper bound .778 .117 .047 .548 1.008
Example 3
Association of Prostate Cancer with 4 kb Deletion in Human mtDNA
Using Needle Biopsy Samples
[0124] Prostate needle biopsy specimens were obtained from 19
individuals, 9 without prostate cancer and 10 with prostate cancer.
Needle biopsy tissues were formalin-fixed paraffin embedded (FFPE)
as is standard in the clinical diagnostic setting. 10 micron
sections of each biopsy were deposited directly into centrifuge
tubes and the DNA was extracted using the QiaAMP DNA Mini Kit
(Qiagen, p/n 51306). DNA extracts were quantified by absorbance at
260 nm using a NanoDrop ND-1000 Spectrophotometer. Yields ranged
from 347 ng to 750 ng. These samples were diluted to 2 ng/ul and
amplification reactions setup according to Table 9 and the
following:
TABLE-US-00012 TABLE 9 Reagents and Concentrations for
Amplification Reaction Final Concen- Reagent tration iQ SYBR Green
Supermix 1X (Bio-Rad Laboratories, p/n 170-8882) Forward Primer
12303-12316/16243-16259F 175 nmol
5'-CCCAAAAATTTTGGTGCAACTCCAAAGCCAC-3' (SEQ ID NO: 6) Reverse Primer
16410R 175 nmol 5'-AGGATGGTGGTCAAGGGAC-3' (SEQ ID NO: 5) DNA
extract 0.8 ng/ul
[0125] Nuclease-free water was added to a final reaction volume of
25 ul. Amplifications were carried out on a DNA Engine Chromo4 Real
Time PCR Instrument (Bio-Rad Laboratories) according the following
cycling conditions:
[0126] 1) 95.degree. C. for 3 minutes
[0127] 2) Followed by 45 cycles of
[0128] 3) 95.degree. C. for 30 seconds
[0129] 4) 69.degree. C. for 30 seconds
[0130] 5) 72.degree. C. for 30 seconds
[0131] 6) Plate Read
Then
[0132] 7) 72.degree. C. for 10 minutes
[0133] 8) Melting Curve 50.degree. C.-105.degree. C. reading every
1.degree. C., hold for 3 seconds
[0134] 9) 4.degree. C. Hold
[0135] Results, shown in Table 10, demonstrate that those
individuals with prostate cancer have a lower C.sub.T value and
therefore higher levels of the 4 kb deletion in prostate tissue
than do those without prostate cancer. Patients with prostate
cancer have an average C.sub.T value of 30.7 while the patients
without prostate cancer have an average C.sub.T value of 36.4. This
difference of 5.7 C.sub.T corresponds to nearly 100 fold greater 4
kb deletion levels in the group with prostate malignancy than in
the group without.
TABLE-US-00013 TABLE 10 Patient Diagnosis and Associated C.sub.T
Score Patient Number and Diagnosis C(t) CUG 1301 Malignant 25.7 CUG
1268 Malignant 27.7 CUG RN 345 Normal 28.3 CUG 1272 Malignant 28.8
CUG 1375 Malignant 29.1 CUG 1259 Malignant 29.1 CUG 1381 Malignant
30.2 CUG RN 82 Normal 30.5 CUG 1372 Malignant 30.9 CUG 1085 C T1
Normal 31.5 CUG 1317 Malignant 31.7 CUG 1377 F Normal 33.6 CUG 1365
B Normal 34.6 CUG 1370 Malignant 35.9 CUG RN 405 Normal 37.5 CUG
1366 Malignant 37.9 CUG RN 701 Normal 41.7 CUG RN 420 Normal 45 CUG
RN 373 Normal 45
[0136] Tables 11 and 12 show the difference in the mean C.sub.T
scores for prostate tissue samples from subjects having normal and
malignant prostate tissue.
TABLE-US-00014 TABLE 11 Mean Values for C.sub.T Score: Prostate
Needle Biopsy Tissue Group N Mean Std. Dev. Std. Error Mean Normal
9 36.4111 6.25229 2.08410 Malignant 10 30.7 3.69534 1.16857
TABLE-US-00015 TABLE 12 Significance Test for C.sub.T Scores
Levene's Test for Equality Means Test for 95% Equality Confidence
of Sig. Std. Interval of the Variances (2- Mean Error Difference
CTt40 fluid F Sig. t df tailed) Diff. Diff. Lower Upper Equal 4.426
.051 2.455 17 .025 5.71111 2.32589 .80391 10.61831 variances
assumed Equal 2.390 12.705 .033 5.71111 2.38935 .53701 10.88522
variances not assumed
[0137] Table 13 and FIG. 6 illustrate that when using a cutoff of
C.sub.T 32.65 the sensitivity and specificity of correctly
diagnosing these patients is 80% and 67% respectively.
TABLE-US-00016 TABLE 13 Determination of Specificity and
Sensitivity Positive if .ltoreq..sup.a Sensitivity 1 - specificity
24.7 .000 .000 26.7 .100 .000 28.0 .200 .000 28.55 .200 .111 28.95
.300 .111 29.65 .500 .111 30.35 .600 .111 30.7 .600 .222 31.2 .700
.222 31.6 .700 .333 32.65 .800 .333 34.1 .800 .444 32.25 .800 .556
36.7 .900 .556 37.7 .900 .667 39.8 1.000 .667 43.35 1.000 .778 46.0
1.000 1.000
[0138] Although the invention has been described with reference to
certain specific embodiments, various modifications thereof will be
apparent to those skilled in the art without departing from the
spirit and scope of the invention as outlined in the claims
appended hereto. All such modifications as would be apparent to one
skilled in the art are intended to be included within the scope of
the following claims. All documents recited in the present
application are incorporated herein by reference.
REFERENCES
[0139] Birch-Machin M A, Online Conference Report (Sunburnt DNA),
International Congress of Biochemistry and Molecular Biology, New
Scientist, 2000(a)
[0140] Birch-Machin M A, Taylor R W, Cochran B, Ackrell B A C,
Tumbull D M. Ann Neurol 48: 330-335, 2000(b)
[0141] Birch-Machin, M. A. (2000). Mitochondria and skin disease.
Clin Exp Dermatol, 25, 141-6.
[0142] Brown, M. D., et al., Am J. Humn Genet, 60: 381-387,
1997
[0143] Bogliolo, M, et al., Mutagenesis, 14: 77-82, 1999
[0144] Chinnery P F and Turnbull D M., Lancet 354 (supplement 1):
17-21, 1999
[0145] Huoponen, Kirsi, Leber hereditary optic neuropathy: clinical
and molecular genetic findings, Neurogenetics (2001) 3:
119-125.
[0146] Hayward S W, Grossfeld G D, Tlsty T D, Cunha G R., Int J
Oncol 13:35-47, 1998
[0147] Huang G M, Ng W L, Farkas J, He L, Liang H A, Gordon D, Hood
R., Genomics 59(2):178-86,1999
[0148] Konishi N, Cho M, Yamamoto K, Hiasa Y. Pathol. Int.
47:735-747,1997
[0149] Landis S H, Murray T, Bolden S, Wingo P A. Cancer J. Clin.
49:8-31
[0150] Lee H C, Lu C Y, Fahn H J, Wei Y Hu. Federation of European
Biochemical Societies, 441:292-296,1998
[0151] Mitochondrial Research Society
http:www.mitoresearch.org/diseases.html.
[0152] MITOMAP: A human mt genome database
(www.gen.emory.edu/mitomap.html)
[0153] Naviaux, R K., Mitochondrial Disease--Primary Care
Physican's Guide. Psy-Ed. Corp D/B/A Exceptional Parents Guide:
3-10, 1997
[0154] Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli
P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S,
Spencer M, Rabitti C, Fazio V M, Sidransky D: Detection of
mitochondrial DNA mutations in primary breast cancer and
fine-needle aspirates. Cancer Res 2001, 61:7623-7626
[0155] Polyak Y, et al., Nature Genet. 20 (3):291-293, 1998
[0156] Seidman, M. D. et al., Arch. Otolaryngol Head Neck Surg.,
123: 1039-1045, 1997
[0157] Sherrat E J, Thomas A W, Alcolado J C., Clin. Sci.
92:225-235,1997
[0158] Shoffner J M, Brown M D, Torroni A, Lott M T, Cabell M F,
Mirra S S, Beal M F, Yang C, Gearing M, Salvo R, Watts R L, Juncos
J L, Hansen L A, Crain B J, Fayad M, Reckford C L, and Wallace D
C., Genomics 17: 171-184, 1993
[0159] SpringNet--CE Connection: Screening, Diagnosis: Improving
Primary Care Outcomes. Website:
http://www.springnet.com/ce/j803a.htm
[0160] Taniike, M. et al., BioChem BioPhys Res Comun, 186: 47-53,
1992
[0161] Valnot, Isabelle, et al., A mitochondrial cytochrome b
mutation but no mutations of nuclearly encoded subunits in
ubiquinol cytochrome c reductase (complex III) deficiency, Human
Genetics (1999) 104: 460-466
[0162] von Wurmb, N, Oehmichen, M, Meissner, C., Mutat Res.
422:247-254, 1998
[0163] Wallace et al., Mitochondiral DNA MUtatio Assoicated with
Leber's Hereditary Optic Neuropathy, Science, 1427-1429
[0164] Wei Y H. Proceedings of the Nat. Sci. Council of the
Republic of China April 22(2):5567, 1998
[0165] Woodwell D A. National Ambulatory Medical Care Survey: 1997
Summary. Advance data from vital and health statistics; no. 305.
Hyattsville, Md.: National Center for Health Statistics. 1999
[0166] Yeh, J. J., et al., Oncogene Journal, 19: 2060-2066,
2000
[0167] Zhang et al., Multiple mitochondiral DNA deletions in an
elderly human individual, FEBS Lett, 297, 34-38 1992
[0168] Zhang, C., et al., BioChem. BioPhys. Res. Comun., 195:
1104-1110, 1993
Sequence CWU 1
1
613926DNAHomo sapiens 1taaaagtaat aaccatgcac actactataa ccaccctaac
cctgacttcc ctaattcccc 60ccatccttac caccctcgtt aaccctaaca aaaaaaactc
atacccccat tatgtaaaat 120ccattgtcgc atccaccttt attatcagtc
tcttccccac aacaatattc atgtgcctag 180accaagaagt tattatctcg
aactgacact gagccacaac ccaaacaacc cagctctccc 240taagcttcaa
actagactac ttctccataa tattcatccc tgtagcattg ttcgttacat
300ggtccatcat agaattctca ctgtgatata taaactcaga cccaaacatt
aatcagttct 360tcaaatatct actcatcttc ctaattacca tactaatctt
agttaccgct aacaacctat 420tccaactgtt catcggctga gagggcgtag
gaattatatc cttcttgctc atcagttgat 480gatacgcccg agcagatgcc
aacacagcag ccattcaagc aatcctatac aaccgtatcg 540gcgatatcgg
tttcatcctc gccttagcat gatttatcct acactccaac tcatgagacc
600cacaacaaat agcccttcta aacgctaatc caagcctcac cccactacta
ggcctcctcc 660tagcagcagc aggcaaatca gcccaattag gtctccaccc
ctgactcccc tcagccatag 720aaggccccac cccagtctca gccctactcc
actcaagcac tatagttgta gcaggaatct 780tcttactcat ccgcttccac
cccctagcag aaaatagccc actaatccaa actctaacac 840tatgcttagg
cgctatcacc actctgttcg cagcagtctg cgcccttaca caaaatgaca
900tcaaaaaaat cgtagccttc tccacttcaa gtcaactagg actcataata
gttacaatcg 960gcatcaacca accacaccta gcattcctgc acatctgtac
ccacgccttc ttcaaagcca 1020tactatttat gtgctccggg tccatcatcc
acaaccttaa caatgaacaa gatattcgaa 1080aaataggagg actactcaaa
accatacctc tcacttcaac ctccctcacc attggcagcc 1140tagcattagc
aggaatacct ttcctcacag gtttctactc caaagaccac atcatcgaaa
1200ccgcaaacat atcatacaca aacgcctgag ccctatctat tactctcatc
gctacctccc 1260tgacaagcgc ctatagcact cgaataattc ttctcaccct
aacaggtcaa cctcgcttcc 1320ccacccttac taacattaac gaaaataacc
ccaccctact aaaccccatt aaacgcctgg 1380cagccggaag cctattcgca
ggatttctca ttactaacaa catttccccc gcatccccct 1440tccaaacaac
aatccccctc tacctaaaac tcacagccct cgctgtcact ttcctaggac
1500ttctaacagc cctagacctc aactacctaa ccaacaaact taaaataaaa
tccccactat 1560gcacatttta tttctccaac atactcggat tctaccctag
catcacacac cgcacaatcc 1620cctatctagg ccttcttacg agccaaaacc
tgcccctact cctcctagac ctaacctgac 1680tagaaaagct attacctaaa
acaatttcac agcaccaaat ctccacctcc atcatcacct 1740caacccaaaa
aggcataatt aaactttact tcctctcttt cttcttccca ctcatcctaa
1800ccctactcct aatcacataa cctattcccc cgagcaatct caattacaat
atatacacca 1860acaaacaatg ttcaaccagt aactactact aatcaacgcc
cataatcata caaagccccc 1920gcaccaatag gatcctcccg aatcaaccct
gacccctctc cttcataaat tattcagctt 1980cctacactat taaagtttac
cacaaccacc accccatcat actctttcac ccacagcacc 2040aatcctacct
ccatcgctaa ccccactaaa acactcacca agacctcaac ccctgacccc
2100catgcctcag gatactcctc aatagccatc gctgtagtat atccaaagac
aaccatcatt 2160ccccctaaat aaattaaaaa aactattaaa cccatataac
ctcccccaaa attcagaata 2220ataacacacc cgaccacacc gctaacaatc
aatactaaac ccccataaat aggagaaggc 2280ttagaagaaa accccacaaa
ccccattact aaacccacac tcaacagaaa caaagcatac 2340atcattattc
tcgcacggac tacaaccacg accaatgata tgaaaaacca tcgttgtatt
2400tcaactacaa gaacaccaat gaccccaata cgcaaaacta accccctaat
aaaattaatt 2460aaccactcat tcatcgacct ccccacccca tccaacatct
ccgcatgatg aaacttcggc 2520tcactccttg gcgcctgcct gatcctccaa
atcaccacag gactattcct agccatgcac 2580tactcaccag acgcctcaac
cgccttttca tcaatcgccc acatcactcg agacgtaaat 2640tatggctgaa
tcatccgcta ccttcacgcc aatggcgcct caatattctt tatctgcctc
2700ttcctacaca tcgggcgagg cctatattac ggatcatttc tctactcaga
aacctgaaac 2760atcggcatta tcctcctgct tgcaactata gcaacagcct
tcataggcta tgtcctcccg 2820tgaggccaaa tatcattctg aggggccaca
gtaattacaa acttactatc cgccatccca 2880tacattggga cagacctagt
tcaatgaatc tgaggaggct actcagtaga cagtcccacc 2940ctcacacgat
tctttacctt tcacttcatc ttgcccttca ttattgcagc cctagcaaca
3000ctccacctcc tattcttgca cgaaacggga tcaaacaacc ccctaggaat
cacctcccat 3060tccgataaaa tcaccttcca cccttactac acaatcaaag
acgccctcgg cttacttctc 3120ttccttctct ccttaatgac attaacacta
ttctcaccag acctcctagg cgacccagac 3180aattataccc tagccaaccc
cttaaacacc cctccccaca tcaagcccga atgatatttc 3240ctattcgcct
acacaattct ccgatccgtc cctaacaaac taggaggcgt ccttgcccta
3300ttactatcca tcctcatcct agcaataatc cccatcctcc atatatccaa
acaacaaagc 3360ataatatttc gcccactaag ccaatcactt tattgactcc
tagccgcaga cctcctcatt 3420ctaacctgaa tcggaggaca accagtaagc
taccctttta ccatcattgg acaagtagca 3480tccgtactat acttcacaac
aatcctaatc ctaataccaa ctatctccct aattgaaaac 3540aaaatactca
aatgggcctg tccttgtagt ataaactaat acaccagtct tgtaaaccgg
3600agatgaaaac ctttttccaa ggacaaatca gagaaaaagt ctttaactcc
accattagca 3660cccaaagcta agattctaat ttaaactatt ctctgttctt
tcatggggaa gcagatttgg 3720gtaccaccca agtattgact cacccatcaa
caaccgctat gtatttcgta cattactgcc 3780agccaccatg aatattgtac
ggtaccataa atacttgacc acctgtagta cataaaaacc 3840caatccacat
caaaaccccc tccccatgct tacaagcaag tacagcaatc aaccctcaac
3900tatcacacat caactgcaac tccaaa 392623926DNAHomo sapiens
2tgcaactcca aataaaagta ataaccatgc acactactat aaccacccta accctgactt
60ccctaattcc ccccatcctt accaccctcg ttaaccctaa caaaaaaaac tcataccccc
120attatgtaaa atccattgtc gcatccacct ttattatcag tctcttcccc
acaacaatat 180tcatgtgcct agaccaagaa gttattatct cgaactgaca
ctgagccaca acccaaacaa 240cccagctctc cctaagcttc aaactagact
acttctccat aatattcatc cctgtagcat 300tgttcgttac atggtccatc
atagaattct cactgtgata tataaactca gacccaaaca 360ttaatcagtt
cttcaaatat ctactcatct tcctaattac catactaatc ttagttaccg
420ctaacaacct attccaactg ttcatcggct gagagggcgt aggaattata
tccttcttgc 480tcatcagttg atgatacgcc cgagcagatg ccaacacagc
agccattcaa gcaatcctat 540acaaccgtat cggcgatatc ggtttcatcc
tcgccttagc atgatttatc ctacactcca 600actcatgaga cccacaacaa
atagcccttc taaacgctaa tccaagcctc accccactac 660taggcctcct
cctagcagca gcaggcaaat cagcccaatt aggtctccac ccctgactcc
720cctcagccat agaaggcccc accccagtct cagccctact ccactcaagc
actatagttg 780tagcaggaat cttcttactc atccgcttcc accccctagc
agaaaatagc ccactaatcc 840aaactctaac actatgctta ggcgctatca
ccactctgtt cgcagcagtc tgcgccctta 900cacaaaatga catcaaaaaa
atcgtagcct tctccacttc aagtcaacta ggactcataa 960tagttacaat
cggcatcaac caaccacacc tagcattcct gcacatctgt acccacgcct
1020tcttcaaagc catactattt atgtgctccg ggtccatcat ccacaacctt
aacaatgaac 1080aagatattcg aaaaatagga ggactactca aaaccatacc
tctcacttca acctccctca 1140ccattggcag cctagcatta gcaggaatac
ctttcctcac aggtttctac tccaaagacc 1200acatcatcga aaccgcaaac
atatcataca caaacgcctg agccctatct attactctca 1260tcgctacctc
cctgacaagc gcctatagca ctcgaataat tcttctcacc ctaacaggtc
1320aacctcgctt ccccaccctt actaacatta acgaaaataa ccccacccta
ctaaacccca 1380ttaaacgcct ggcagccgga agcctattcg caggatttct
cattactaac aacatttccc 1440ccgcatcccc cttccaaaca acaatccccc
tctacctaaa actcacagcc ctcgctgtca 1500ctttcctagg acttctaaca
gccctagacc tcaactacct aaccaacaaa cttaaaataa 1560aatccccact
atgcacattt tatttctcca acatactcgg attctaccct agcatcacac
1620accgcacaat cccctatcta ggccttctta cgagccaaaa cctgccccta
ctcctcctag 1680acctaacctg actagaaaag ctattaccta aaacaatttc
acagcaccaa atctccacct 1740ccatcatcac ctcaacccaa aaaggcataa
ttaaacttta cttcctctct ttcttcttcc 1800cactcatcct aaccctactc
ctaatcacat aacctattcc cccgagcaat ctcaattaca 1860atatatacac
caacaaacaa tgttcaacca gtaactacta ctaatcaacg cccataatca
1920tacaaagccc ccgcaccaat aggatcctcc cgaatcaacc ctgacccctc
tccttcataa 1980attattcagc ttcctacact attaaagttt accacaacca
ccaccccatc atactctttc 2040acccacagca ccaatcctac ctccatcgct
aaccccacta aaacactcac caagacctca 2100acccctgacc cccatgcctc
aggatactcc tcaatagcca tcgctgtagt atatccaaag 2160acaaccatca
ttccccctaa ataaattaaa aaaactatta aacccatata acctccccca
2220aaattcagaa taataacaca cccgaccaca ccgctaacaa tcaatactaa
acccccataa 2280ataggagaag gcttagaaga aaaccccaca aaccccatta
ctaaacccac actcaacaga 2340aacaaagcat acatcattat tctcgcacgg
actacaacca cgaccaatga tatgaaaaac 2400catcgttgta tttcaactac
aagaacacca atgaccccaa tacgcaaaac taacccccta 2460ataaaattaa
ttaaccactc attcatcgac ctccccaccc catccaacat ctccgcatga
2520tgaaacttcg gctcactcct tggcgcctgc ctgatcctcc aaatcaccac
aggactattc 2580ctagccatgc actactcacc agacgcctca accgcctttt
catcaatcgc ccacatcact 2640cgagacgtaa attatggctg aatcatccgc
taccttcacg ccaatggcgc ctcaatattc 2700tttatctgcc tcttcctaca
catcgggcga ggcctatatt acggatcatt tctctactca 2760gaaacctgaa
acatcggcat tatcctcctg cttgcaacta tagcaacagc cttcataggc
2820tatgtcctcc cgtgaggcca aatatcattc tgaggggcca cagtaattac
aaacttacta 2880tccgccatcc catacattgg gacagaccta gttcaatgaa
tctgaggagg ctactcagta 2940gacagtccca ccctcacacg attctttacc
tttcacttca tcttgccctt cattattgca 3000gccctagcaa cactccacct
cctattcttg cacgaaacgg gatcaaacaa ccccctagga 3060atcacctccc
attccgataa aatcaccttc cacccttact acacaatcaa agacgccctc
3120ggcttacttc tcttccttct ctccttaatg acattaacac tattctcacc
agacctccta 3180ggcgacccag acaattatac cctagccaac cccttaaaca
cccctcccca catcaagccc 3240gaatgatatt tcctattcgc ctacacaatt
ctccgatccg tccctaacaa actaggaggc 3300gtccttgccc tattactatc
catcctcatc ctagcaataa tccccatcct ccatatatcc 3360aaacaacaaa
gcataatatt tcgcccacta agccaatcac tttattgact cctagccgca
3420gacctcctca ttctaacctg aatcggagga caaccagtaa gctacccttt
taccatcatt 3480ggacaagtag catccgtact atacttcaca acaatcctaa
tcctaatacc aactatctcc 3540ctaattgaaa acaaaatact caaatgggcc
tgtccttgta gtataaacta atacaccagt 3600cttgtaaacc ggagatgaaa
acctttttcc aaggacaaat cagagaaaaa gtctttaact 3660ccaccattag
cacccaaagc taagattcta atttaaacta ttctctgttc tttcatgggg
3720aagcagattt gggtaccacc caagtattga ctcacccatc aacaaccgct
atgtatttcg 3780tacattactg ccagccacca tgaatattgt acggtaccat
aaatacttga ccacctgtag 3840tacataaaaa cccaatccac atcaaaaccc
cctccccatg cttacaagca agtacagcaa 3900tcaaccctca actatcacac atcaac
3926316569DNAHomo sapiensmisc_feature(3107)..(3107)n is a, c, g, or
t 3gatcacaggt ctatcaccct attaaccact cacgggagct ctccatgcat
ttggtatttt 60cgtctggggg gtatgcacgc gatagcattg cgagacgctg gagccggagc
accctatgtc 120gcagtatctg tctttgattc ctgcctcatc ctattattta
tcgcacctac gttcaatatt 180acaggcgaac atacttacta aagtgtgtta
attaattaat gcttgtagga cataataata 240acaattgaat gtctgcacag
ccactttcca cacagacatc ataacaaaaa atttccacca 300aaccccccct
cccccgcttc tggccacagc acttaaacac atctctgcca aaccccaaaa
360acaaagaacc ctaacaccag cctaaccaga tttcaaattt tatcttttgg
cggtatgcac 420ttttaacagt caccccccaa ctaacacatt attttcccct
cccactccca tactactaat 480ctcatcaata caacccccgc ccatcctacc
cagcacacac acaccgctgc taaccccata 540ccccgaacca accaaacccc
aaagacaccc cccacagttt atgtagctta cctcctcaaa 600gcaatacact
gaaaatgttt agacgggctc acatcacccc ataaacaaat aggtttggtc
660ctagcctttc tattagctct tagtaagatt acacatgcaa gcatccccgt
tccagtgagt 720tcaccctcta aatcaccacg atcaaaagga acaagcatca
agcacgcagc aatgcagctc 780aaaacgctta gcctagccac acccccacgg
gaaacagcag tgattaacct ttagcaataa 840acgaaagttt aactaagcta
tactaacccc agggttggtc aatttcgtgc cagccaccgc 900ggtcacacga
ttaacccaag tcaatagaag ccggcgtaaa gagtgtttta gatcaccccc
960tccccaataa agctaaaact cacctgagtt gtaaaaaact ccagttgaca
caaaatagac 1020tacgaaagtg gctttaacat atctgaacac acaatagcta
agacccaaac tgggattaga 1080taccccacta tgcttagccc taaacctcaa
cagttaaatc aacaaaactg ctcgccagaa 1140cactacgagc cacagcttaa
aactcaaagg acctggcggt gcttcatatc cctctagagg 1200agcctgttct
gtaatcgata aaccccgatc aacctcacca cctcttgctc agcctatata
1260ccgccatctt cagcaaaccc tgatgaaggc tacaaagtaa gcgcaagtac
ccacgtaaag 1320acgttaggtc aaggtgtagc ccatgaggtg gcaagaaatg
ggctacattt tctaccccag 1380aaaactacga tagcccttat gaaacttaag
ggtcgaaggt ggatttagca gtaaactaag 1440agtagagtgc ttagttgaac
agggccctga agcgcgtaca caccgcccgt caccctcctc 1500aagtatactt
caaaggacat ttaactaaaa cccctacgca tttatataga ggagacaagt
1560cgtaacatgg taagtgtact ggaaagtgca cttggacgaa ccagagtgta
gcttaacaca 1620aagcacccaa cttacactta ggagatttca acttaacttg
accgctctga gctaaaccta 1680gccccaaacc cactccacct tactaccaga
caaccttagc caaaccattt acccaaataa 1740agtataggcg atagaaattg
aaacctggcg caatagatat agtaccgcaa gggaaagatg 1800aaaaattata
accaagcata atatagcaag gactaacccc tataccttct gcataatgaa
1860ttaactagaa ataactttgc aaggagagcc aaagctaaga cccccgaaac
cagacgagct 1920acctaagaac agctaaaaga gcacacccgt ctatgtagca
aaatagtggg aagatttata 1980ggtagaggcg acaaacctac cgagcctggt
gatagctggt tgtccaagat agaatcttag 2040ttcaacttta aatttgccca
cagaaccctc taaatcccct tgtaaattta actgttagtc 2100caaagaggaa
cagctctttg gacactagga aaaaaccttg tagagagagt aaaaaattta
2160acacccatag taggcctaaa agcagccacc aattaagaaa gcgttcaagc
tcaacaccca 2220ctacctaaaa aatcccaaac atataactga actcctcaca
cccaattgga ccaatctatc 2280accctataga agaactaatg ttagtataag
taacatgaaa acattctcct ccgcataagc 2340ctgcgtcaga ttaaaacact
gaactgacaa ttaacagccc aatatctaca atcaaccaac 2400aagtcattat
taccctcact gtcaacccaa cacaggcatg ctcataagga aaggttaaaa
2460aaagtaaaag gaactcggca aatcttaccc cgcctgttta ccaaaaacat
cacctctagc 2520atcaccagta ttagaggcac cgcctgccca gtgacacatg
tttaacggcc gcggtaccct 2580aaccgtgcaa aggtagcata atcacttgtt
ccttaaatag ggacctgtat gaatggctcc 2640acgagggttc agctgtctct
tacttttaac cagtgaaatt gacctgcccg tgaagaggcg 2700ggcataacac
agcaagacga gaagacccta tggagcttta atttattaat gcaaacagta
2760cctaacaaac ccacaggtcc taaactacca aacctgcatt aaaaatttcg
gttggggcga 2820cctcggagca gaacccaacc tccgagcagt acatgctaag
acttcaccag tcaaagcgaa 2880ctactatact caattgatcc aataacttga
ccaacggaac aagttaccct agggataaca 2940gcgcaatcct attctagagt
ccatatcaac aatagggttt acgacctcga tgttggatca 3000ggacatcccg
atggtgcagc cgctattaaa ggttcgtttg ttcaacgatt aaagtcctac
3060gtgatctgag ttcagaccgg agtaatccag gtcggtttct atctacnttc
aaattcctcc 3120ctgtacgaaa ggacaagaga aataaggcct acttcacaaa
gcgccttccc ccgtaaatga 3180tatcatctca acttagtatt atacccacac
ccacccaaga acagggtttg ttaagatggc 3240agagcccggt aatcgcataa
aacttaaaac tttacagtca gaggttcaat tcctcttctt 3300aacaacatac
ccatggccaa cctcctactc ctcattgtac ccattctaat cgcaatggca
3360ttcctaatgc ttaccgaacg aaaaattcta ggctatatac aactacgcaa
aggccccaac 3420gttgtaggcc cctacgggct actacaaccc ttcgctgacg
ccataaaact cttcaccaaa 3480gagcccctaa aacccgccac atctaccatc
accctctaca tcaccgcccc gaccttagct 3540ctcaccatcg ctcttctact
atgaaccccc ctccccatac ccaaccccct ggtcaacctc 3600aacctaggcc
tcctatttat tctagccacc tctagcctag ccgtttactc aatcctctga
3660tcagggtgag catcaaactc aaactacgcc ctgatcggcg cactgcgagc
agtagcccaa 3720acaatctcat atgaagtcac cctagccatc attctactat
caacattact aataagtggc 3780tcctttaacc tctccaccct tatcacaaca
caagaacacc tctgattact cctgccatca 3840tgacccttgg ccataatatg
atttatctcc acactagcag agaccaaccg aacccccttc 3900gaccttgccg
aaggggagtc cgaactagtc tcaggcttca acatcgaata cgccgcaggc
3960cccttcgccc tattcttcat agccgaatac acaaacatta ttataataaa
caccctcacc 4020actacaatct tcctaggaac aacatatgac gcactctccc
ctgaactcta cacaacatat 4080tttgtcacca agaccctact tctaacctcc
ctgttcttat gaattcgaac agcatacccc 4140cgattccgct acgaccaact
catacacctc ctatgaaaaa acttcctacc actcacccta 4200gcattactta
tatgatatgt ctccataccc attacaatct ccagcattcc ccctcaaacc
4260taagaaatat gtctgataaa agagttactt tgatagagta aataatagga
gcttaaaccc 4320ccttatttct aggactatga gaatcgaacc catccctgag
aatccaaaat tctccgtgcc 4380acctatcaca ccccatccta aagtaaggtc
agctaaataa gctatcgggc ccataccccg 4440aaaatgttgg ttataccctt
cccgtactaa ttaatcccct ggcccaaccc gtcatctact 4500ctaccatctt
tgcaggcaca ctcatcacag cgctaagctc gcactgattt tttacctgag
4560taggcctaga aataaacatg ctagctttta ttccagttct aaccaaaaaa
ataaaccctc 4620gttccacaga agctgccatc aagtatttcc tcacgcaagc
aaccgcatcc ataatccttc 4680taatagctat cctcttcaac aatatactct
ccggacaatg aaccataacc aatactacca 4740atcaatactc atcattaata
atcataatag ctatagcaat aaaactagga atagccccct 4800ttcacttctg
agtcccagag gttacccaag gcacccctct gacatccggc ctgcttcttc
4860tcacatgaca aaaactagcc cccatctcaa tcatatacca aatctctccc
tcactaaacg 4920taagccttct cctcactctc tcaatcttat ccatcatagc
aggcagttga ggtggattaa 4980accaaaccca gctacgcaaa atcttagcat
actcctcaat tacccacata ggatgaataa 5040tagcagttct accgtacaac
cctaacataa ccattcttaa tttaactatt tatattatcc 5100taactactac
cgcattccta ctactcaact taaactccag caccacgacc ctactactat
5160ctcgcacctg aaacaagcta acatgactaa cacccttaat tccatccacc
ctcctctccc 5220taggaggcct gcccccgcta accggctttt tgcccaaatg
ggccattatc gaagaattca 5280caaaaaacaa tagcctcatc atccccacca
tcatagccac catcaccctc cttaacctct 5340acttctacct acgcctaatc
tactccacct caatcacact actccccata tctaacaacg 5400taaaaataaa
atgacagttt gaacatacaa aacccacccc attcctcccc acactcatcg
5460cccttaccac gctactccta cctatctccc cttttatact aataatctta
tagaaattta 5520ggttaaatac agaccaagag ccttcaaagc cctcagtaag
ttgcaatact taatttctgt 5580aacagctaag gactgcaaaa ccccactctg
catcaactga acgcaaatca gccactttaa 5640ttaagctaag cccttactag
accaatggga cttaaaccca caaacactta gttaacagct 5700aagcacccta
atcaactggc ttcaatctac ttctcccgcc gccgggaaaa aaggcgggag
5760aagccccggc aggtttgaag ctgcttcttc gaatttgcaa ttcaatatga
aaatcacctc 5820ggagctggta aaaagaggcc taacccctgt ctttagattt
acagtccaat gcttcactca 5880gccattttac ctcaccccca ctgatgttcg
ccgaccgttg actattctct acaaaccaca 5940aagacattgg aacactatac
ctattattcg gcgcatgagc tggagtccta ggcacagctc 6000taagcctcct
tattcgagcc gagctgggcc agccaggcaa ccttctaggt aacgaccaca
6060tctacaacgt tatcgtcaca gcccatgcat ttgtaataat cttcttcata
gtaataccca 6120tcataatcgg aggctttggc aactgactag ttcccctaat
aatcggtgcc cccgatatgg 6180cgtttccccg cataaacaac ataagcttct
gactcttacc tccctctctc ctactcctgc 6240tcgcatctgc tatagtggag
gccggagcag gaacaggttg aacagtctac cctcccttag 6300cagggaacta
ctcccaccct ggagcctccg tagacctaac catcttctcc ttacacctag
6360caggtgtctc ctctatctta ggggccatca atttcatcac aacaattatc
aatataaaac 6420cccctgccat aacccaatac caaacgcccc tcttcgtctg
atccgtccta atcacagcag 6480tcctacttct cctatctctc ccagtcctag
ctgctggcat cactatacta ctaacagacc 6540gcaacctcaa caccaccttc
ttcgaccccg ccggaggagg agaccccatt ctataccaac 6600acctattctg
atttttcggt caccctgaag tttatattct tatcctacca ggcttcggaa
6660taatctccca tattgtaact tactactccg gaaaaaaaga accatttgga
tacataggta 6720tggtctgagc tatgatatca attggcttcc tagggtttat
cgtgtgagca caccatatat 6780ttacagtagg aatagacgta gacacacgag
catatttcac ctccgctacc ataatcatcg 6840ctatccccac cggcgtcaaa
gtatttagct gactcgccac actccacgga agcaatatga 6900aatgatctgc
tgcagtgctc tgagccctag gattcatctt tcttttcacc gtaggtggcc
6960tgactggcat tgtattagca aactcatcac tagacatcgt actacacgac
acgtactacg 7020ttgtagccca
cttccactat gtcctatcaa taggagctgt atttgccatc ataggaggct
7080tcattcactg atttccccta ttctcaggct acaccctaga ccaaacctac
gccaaaatcc 7140atttcactat catattcatc ggcgtaaatc taactttctt
cccacaacac tttctcggcc 7200tatccggaat gccccgacgt tactcggact
accccgatgc atacaccaca tgaaacatcc 7260tatcatctgt aggctcattc
atttctctaa cagcagtaat attaataatt ttcatgattt 7320gagaagcctt
cgcttcgaag cgaaaagtcc taatagtaga agaaccctcc ataaacctgg
7380agtgactata tggatgcccc ccaccctacc acacattcga agaacccgta
tacataaaat 7440ctagacaaaa aaggaaggaa tcgaaccccc caaagctggt
ttcaagccaa ccccatggcc 7500tccatgactt tttcaaaaag gtattagaaa
aaccatttca taactttgtc aaagttaaat 7560tataggctaa atcctatata
tcttaatggc acatgcagcg caagtaggtc tacaagacgc 7620tacttcccct
atcatagaag agcttatcac ctttcatgat cacgccctca taatcatttt
7680ccttatctgc ttcctagtcc tgtatgccct tttcctaaca ctcacaacaa
aactaactaa 7740tactaacatc tcagacgctc aggaaataga aaccgtctga
actatcctgc ccgccatcat 7800cctagtcctc atcgccctcc catccctacg
catcctttac ataacagacg aggtcaacga 7860tccctccctt accatcaaat
caattggcca ccaatggtac tgaacctacg agtacaccga 7920ctacggcgga
ctaatcttca actcctacat acttccccca ttattcctag aaccaggcga
7980cctgcgactc cttgacgttg acaatcgagt agtactcccg attgaagccc
ccattcgtat 8040aataattaca tcacaagacg tcttgcactc atgagctgtc
cccacattag gcttaaaaac 8100agatgcaatt cccggacgtc taaaccaaac
cactttcacc gctacacgac cgggggtata 8160ctacggtcaa tgctctgaaa
tctgtggagc aaaccacagt ttcatgccca tcgtcctaga 8220attaattccc
ctaaaaatct ttgaaatagg gcccgtattt accctatagc accccctcta
8280ccccctctag agcccactgt aaagctaact tagcattaac cttttaagtt
aaagattaag 8340agaaccaaca cctctttaca gtgaaatgcc ccaactaaat
actaccgtat ggcccaccat 8400aattaccccc atactcctta cactattcct
catcacccaa ctaaaaatat taaacacaaa 8460ctaccaccta cctccctcac
caaagcccat aaaaataaaa aattataaca aaccctgaga 8520accaaaatga
acgaaaatct gttcgcttca ttcattgccc ccacaatcct aggcctaccc
8580gccgcagtac tgatcattct atttccccct ctattgatcc ccacctccaa
atatctcatc 8640aacaaccgac taatcaccac ccaacaatga ctaatcaaac
taacctcaaa acaaatgata 8700accatacaca acactaaagg acgaacctga
tctcttatac tagtatcctt aatcattttt 8760attgccacaa ctaacctcct
cggactcctg cctcactcat ttacaccaac cacccaacta 8820tctataaacc
tagccatggc catcccctta tgagcgggca cagtgattat aggctttcgc
8880tctaagatta aaaatgccct agcccacttc ttaccacaag gcacacctac
accccttatc 8940cccatactag ttattatcga aaccatcagc ctactcattc
aaccaatagc cctggccgta 9000cgcctaaccg ctaacattac tgcaggccac
ctactcatgc acctaattgg aagcgccacc 9060ctagcaatat caaccattaa
ccttccctct acacttatca tcttcacaat tctaattcta 9120ctgactatcc
tagaaatcgc tgtcgcctta atccaagcct acgttttcac acttctagta
9180agcctctacc tgcacgacaa cacataatga cccaccaatc acatgcctat
catatagtaa 9240aacccagccc atgaccccta acaggggccc tctcagccct
cctaatgacc tccggcctag 9300ccatgtgatt tcacttccac tccataacgc
tcctcatact aggcctacta accaacacac 9360taaccatata ccaatgatgg
cgcgatgtaa cacgagaaag cacataccaa ggccaccaca 9420caccacctgt
ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt
9480ttttcttcgc aggatttttc tgagcctttt accactccag cctagcccct
accccccaat 9540taggagggca ctggccccca acaggcatca ccccgctaaa
tcccctagaa gtcccactcc 9600taaacacatc cgtattactc gcatcaggag
tatcaatcac ctgagctcac catagtctaa 9660tagaaaacaa ccgaaaccaa
ataattcaag cactgcttat tacaatttta ctgggtctct 9720attttaccct
cctacaagcc tcagagtact tcgagtctcc cttcaccatt tccgacggca
9780tctacggctc aacatttttt gtagccacag gcttccacgg acttcacgtc
attattggct 9840caactttcct cactatctgc ttcatccgcc aactaatatt
tcactttaca tccaaacatc 9900actttggctt cgaagccgcc gcctgatact
ggcattttgt agatgtggtt tgactatttc 9960tgtatgtctc catctattga
tgagggtctt actcttttag tataaatagt accgttaact 10020tccaattaac
tagttttgac aacattcaaa aaagagtaat aaacttcgcc ttaattttaa
10080taatcaacac cctcctagcc ttactactaa taattattac attttgacta
ccacaactca 10140acggctacat agaaaaatcc accccttacg agtgcggctt
cgaccctata tcccccgccc 10200gcgtcccttt ctccataaaa ttcttcttag
tagctattac cttcttatta tttgatctag 10260aaattgccct ccttttaccc
ctaccatgag ccctacaaac aactaacctg ccactaatag 10320ttatgtcatc
cctcttatta atcatcatcc tagccctaag tctggcctat gagtgactac
10380aaaaaggatt agactgaacc gaattggtat atagtttaaa caaaacgaat
gatttcgact 10440cattaaatta tgataatcat atttaccaaa tgcccctcat
ttacataaat attatactag 10500catttaccat ctcacttcta ggaatactag
tatatcgctc acacctcata tcctccctac 10560tatgcctaga aggaataata
ctatcgctgt tcattatagc tactctcata accctcaaca 10620cccactccct
cttagccaat attgtgccta ttgccatact agtctttgcc gcctgcgaag
10680cagcggtggg cctagcccta ctagtctcaa tctccaacac atatggccta
gactacgtac 10740ataacctaaa cctactccaa tgctaaaact aatcgtccca
acaattatat tactaccact 10800gacatgactt tccaaaaaac acataatttg
aatcaacaca accacccaca gcctaattat 10860tagcatcatc cctctactat
tttttaacca aatcaacaac aacctattta gctgttcccc 10920aaccttttcc
tccgaccccc taacaacccc cctcctaata ctaactacct gactcctacc
10980cctcacaatc atggcaagcc aacgccactt atccagtgaa ccactatcac
gaaaaaaact 11040ctacctctct atactaatct ccctacaaat ctccttaatt
ataacattca cagccacaga 11100actaatcata ttttatatct tcttcgaaac
cacacttatc cccaccttgg ctatcatcac 11160ccgatgaggc aaccagccag
aacgcctgaa cgcaggcaca tacttcctat tctacaccct 11220agtaggctcc
cttcccctac tcatcgcact aatttacact cacaacaccc taggctcact
11280aaacattcta ctactcactc tcactgccca agaactatca aactcctgag
ccaacaactt 11340aatatgacta gcttacacaa tagcttttat agtaaagata
cctctttacg gactccactt 11400atgactccct aaagcccatg tcgaagcccc
catcgctggg tcaatagtac ttgccgcagt 11460actcttaaaa ctaggcggct
atggtataat acgcctcaca ctcattctca accccctgac 11520aaaacacata
gcctacccct tccttgtact atccctatga ggcataatta taacaagctc
11580catctgccta cgacaaacag acctaaaatc gctcattgca tactcttcaa
tcagccacat 11640agccctcgta gtaacagcca ttctcatcca aaccccctga
agcttcaccg gcgcagtcat 11700tctcataatc gcccacgggc ttacatcctc
attactattc tgcctagcaa actcaaacta 11760cgaacgcact cacagtcgca
tcataatcct ctctcaagga cttcaaactc tactcccact 11820aatagctttt
tgatgacttc tagcaagcct cgctaacctc gccttacccc ccactattaa
11880cctactggga gaactctctg tgctagtaac cacgttctcc tgatcaaata
tcactctcct 11940acttacagga ctcaacatac tagtcacagc cctatactcc
ctctacatat ttaccacaac 12000acaatggggc tcactcaccc accacattaa
caacataaaa ccctcattca cacgagaaaa 12060caccctcatg ttcatacacc
tatcccccat tctcctccta tccctcaacc ccgacatcat 12120taccgggttt
tcctcttgta aatatagttt aaccaaaaca tcagattgtg aatctgacaa
12180cagaggctta cgacccctta tttaccgaga aagctcacaa gaactgctaa
ctcatgcccc 12240catgtctaac aacatggctt tctcaacttt taaaggataa
cagctatcca ttggtcttag 12300gccccaaaaa ttttggtgca actccaaata
aaagtaataa ccatgcacac tactataacc 12360accctaaccc tgacttccct
aattcccccc atccttacca ccctcgttaa ccctaacaaa 12420aaaaactcat
acccccatta tgtaaaatcc attgtcgcat ccacctttat tatcagtctc
12480ttccccacaa caatattcat gtgcctagac caagaagtta ttatctcgaa
ctgacactga 12540gccacaaccc aaacaaccca gctctcccta agcttcaaac
tagactactt ctccataata 12600ttcatccctg tagcattgtt cgttacatgg
tccatcatag aattctcact gtgatatata 12660aactcagacc caaacattaa
tcagttcttc aaatatctac tcatcttcct aattaccata 12720ctaatcttag
ttaccgctaa caacctattc caactgttca tcggctgaga gggcgtagga
12780attatatcct tcttgctcat cagttgatga tacgcccgag cagatgccaa
cacagcagcc 12840attcaagcaa tcctatacaa ccgtatcggc gatatcggtt
tcatcctcgc cttagcatga 12900tttatcctac actccaactc atgagaccca
caacaaatag cccttctaaa cgctaatcca 12960agcctcaccc cactactagg
cctcctccta gcagcagcag gcaaatcagc ccaattaggt 13020ctccacccct
gactcccctc agccatagaa ggccccaccc cagtctcagc cctactccac
13080tcaagcacta tagttgtagc aggaatcttc ttactcatcc gcttccaccc
cctagcagaa 13140aatagcccac taatccaaac tctaacacta tgcttaggcg
ctatcaccac tctgttcgca 13200gcagtctgcg cccttacaca aaatgacatc
aaaaaaatcg tagccttctc cacttcaagt 13260caactaggac tcataatagt
tacaatcggc atcaaccaac cacacctagc attcctgcac 13320atctgtaccc
acgccttctt caaagccata ctatttatgt gctccgggtc catcatccac
13380aaccttaaca atgaacaaga tattcgaaaa ataggaggac tactcaaaac
catacctctc 13440acttcaacct ccctcaccat tggcagccta gcattagcag
gaataccttt cctcacaggt 13500ttctactcca aagaccacat catcgaaacc
gcaaacatat catacacaaa cgcctgagcc 13560ctatctatta ctctcatcgc
tacctccctg acaagcgcct atagcactcg aataattctt 13620ctcaccctaa
caggtcaacc tcgcttcccc acccttacta acattaacga aaataacccc
13680accctactaa accccattaa acgcctggca gccggaagcc tattcgcagg
atttctcatt 13740actaacaaca tttcccccgc atcccccttc caaacaacaa
tccccctcta cctaaaactc 13800acagccctcg ctgtcacttt cctaggactt
ctaacagccc tagacctcaa ctacctaacc 13860aacaaactta aaataaaatc
cccactatgc acattttatt tctccaacat actcggattc 13920taccctagca
tcacacaccg cacaatcccc tatctaggcc ttcttacgag ccaaaacctg
13980cccctactcc tcctagacct aacctgacta gaaaagctat tacctaaaac
aatttcacag 14040caccaaatct ccacctccat catcacctca acccaaaaag
gcataattaa actttacttc 14100ctctctttct tcttcccact catcctaacc
ctactcctaa tcacataacc tattcccccg 14160agcaatctca attacaatat
atacaccaac aaacaatgtt caaccagtaa ctactactaa 14220tcaacgccca
taatcataca aagcccccgc accaatagga tcctcccgaa tcaaccctga
14280cccctctcct tcataaatta ttcagcttcc tacactatta aagtttacca
caaccaccac 14340cccatcatac tctttcaccc acagcaccaa tcctacctcc
atcgctaacc ccactaaaac 14400actcaccaag acctcaaccc ctgaccccca
tgcctcagga tactcctcaa tagccatcgc 14460tgtagtatat ccaaagacaa
ccatcattcc ccctaaataa attaaaaaaa ctattaaacc 14520catataacct
cccccaaaat tcagaataat aacacacccg accacaccgc taacaatcaa
14580tactaaaccc ccataaatag gagaaggctt agaagaaaac cccacaaacc
ccattactaa 14640acccacactc aacagaaaca aagcatacat cattattctc
gcacggacta caaccacgac 14700caatgatatg aaaaaccatc gttgtatttc
aactacaaga acaccaatga ccccaatacg 14760caaaactaac cccctaataa
aattaattaa ccactcattc atcgacctcc ccaccccatc 14820caacatctcc
gcatgatgaa acttcggctc actccttggc gcctgcctga tcctccaaat
14880caccacagga ctattcctag ccatgcacta ctcaccagac gcctcaaccg
ccttttcatc 14940aatcgcccac atcactcgag acgtaaatta tggctgaatc
atccgctacc ttcacgccaa 15000tggcgcctca atattcttta tctgcctctt
cctacacatc gggcgaggcc tatattacgg 15060atcatttctc tactcagaaa
cctgaaacat cggcattatc ctcctgcttg caactatagc 15120aacagccttc
ataggctatg tcctcccgtg aggccaaata tcattctgag gggccacagt
15180aattacaaac ttactatccg ccatcccata cattgggaca gacctagttc
aatgaatctg 15240aggaggctac tcagtagaca gtcccaccct cacacgattc
tttacctttc acttcatctt 15300gcccttcatt attgcagccc tagcaacact
ccacctccta ttcttgcacg aaacgggatc 15360aaacaacccc ctaggaatca
cctcccattc cgataaaatc accttccacc cttactacac 15420aatcaaagac
gccctcggct tacttctctt ccttctctcc ttaatgacat taacactatt
15480ctcaccagac ctcctaggcg acccagacaa ttatacccta gccaacccct
taaacacccc 15540tccccacatc aagcccgaat gatatttcct attcgcctac
acaattctcc gatccgtccc 15600taacaaacta ggaggcgtcc ttgccctatt
actatccatc ctcatcctag caataatccc 15660catcctccat atatccaaac
aacaaagcat aatatttcgc ccactaagcc aatcacttta 15720ttgactccta
gccgcagacc tcctcattct aacctgaatc ggaggacaac cagtaagcta
15780cccttttacc atcattggac aagtagcatc cgtactatac ttcacaacaa
tcctaatcct 15840aataccaact atctccctaa ttgaaaacaa aatactcaaa
tgggcctgtc cttgtagtat 15900aaactaatac accagtcttg taaaccggag
atgaaaacct ttttccaagg acaaatcaga 15960gaaaaagtct ttaactccac
cattagcacc caaagctaag attctaattt aaactattct 16020ctgttctttc
atggggaagc agatttgggt accacccaag tattgactca cccatcaaca
16080accgctatgt atttcgtaca ttactgccag ccaccatgaa tattgtacgg
taccataaat 16140acttgaccac ctgtagtaca taaaaaccca atccacatca
aaaccccctc cccatgctta 16200caagcaagta cagcaatcaa ccctcaacta
tcacacatca actgcaactc caaagccacc 16260cctcacccac taggatacca
acaaacctac ccacccttaa cagtacatag tacataaagc 16320catttaccgt
acatagcaca ttacagtcaa atcccttctc gtccccatgg atgacccccc
16380tcagataggg gtcccttgac caccatcctc cgtgaaatca atatcccgca
caagagtgct 16440actctcctcg ctccgggccc ataacacttg ggggtagcta
aagtgaactg tatccgacat 16500ctggttccta cttcagggtc ataaagccta
aatagcccac acgttcccct taaataagac 16560atcacgatg
16569429DNAArtificialSynthetic primer 4ttggtgcaac tccaaagcca
cccctcacc 29519DNAartificialSynthetic primer. 5aggatggtgg tcaagggac
19631DNAArtificialSynthetic primer 6cccaaaaatt ttggtgcaac
tccaaagcca c 31
* * * * *
References